Quintiles Transitional Holdings (Q) has risen sharply, recording gains of 1.38% in the past 4 weeks. However, the stock has corrected -1.77% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.99% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Quintiles Transnational Holdings Inc. is up 12.77% in the last 3-month period. Year-to-Date the stock performance stands at 9.31%. The stock has recorded a 20-day Moving Average of 1.81% and the 50-Day Moving Average is 5.77%.
Quintiles Transitional Holdings (NYSE:Q): The stock opened at $75.12 on Friday but the bulls could not build on the opening and the stock topped out at $75.13 for the day. The stock traded down to $74.45 during the day, due to lack of any buying support eventually closed down at $75.05 with a loss of -0.28% for the day. The stock had closed at $75.26 on the previous day. The total traded volume was 760,982 shares.
Also, Equity Analysts at the Citigroup maintains the rating on Quintiles Transitional Holdings (NYSE:Q). The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency raises the price target from $72 per share to $75 per share. The rating by the firm was issued on July 28, 2016.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.